FDA Submission And US Launch Will Drive Success

Published
19 Mar 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
SEK 421.20
27.5% undervalued intrinsic discount
08 Aug
SEK 305.40
Loading
1Y
10.3%
7D
-4.1%

Author's Valuation

SEK 421.2

27.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 13%

Shared on24 Apr 25
Fair value Decreased 1.50%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has decreased revenue growth from 44.3% to 38.4%, decreased profit margin from 35.1% to 31.5% and increased future PE multiple from 35.7x to 45.2x.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 3.91%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.